FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

Core Viewpoint - The law firm Halper Sadeh LLC is investigating the fairness of the sale of Amicus Therapeutics, Inc. to BioMarin Pharmaceutical Inc. at a price of $14.50 per share for Amicus shareholders [1]. Company Summary - Amicus Therapeutics, Inc. is being sold to BioMarin Pharmaceutical Inc. for $14.50 per share [1]. - The investigation by Halper Sadeh LLC focuses on whether this sale price is fair to Amicus shareholders [1]. Legal Rights and Options - Halper Sadeh encourages Amicus shareholders to learn more about their legal rights and options regarding the sale [1]. - Shareholders can contact Daniel Sadeh or Zachary Halper for further information [1].